Research Project
Grant-in-Aid for Scientific Research (C)
Since the infection of virus is likely to occur in populations most often through exposure to mucosal tissue, virus-specific immune responses at mucosal sites are critical for the initial control of infection. A non-replicating vaccine vector to digestive tract mucosa by oral administration is potentially powerful in mucosal vaccine, but suitable vectors have not yet been reported. In the present study, we show two types of novel mucosal vaccine and combined these two attempts by using virus-like particle(VLP) composed of open reading frame 2 of hepatitis E virus(HEV). One is chimeric HEV-VLP having human immunodeficiency virus(HIV) env epitope to stimulate mucosal immunity without the need for adjuvant by oral administration. Another-vaccine using HEV-VLP is attempt to package HIV env DNA in vitro and then to deliver this foreign DNA to intestinal mucosa in vivo as a DNA vaccine carrier. Both these two types of vaccines elicited HIV env specific mucosal and systemic humoral as well as cellular immune responses without any kind of adjuvant through oral administration. These findings provide evidences for the possibility of VLP derived from orally transmissible virus as a vaccine vector to mucosal tissue by oral administration.
All 2004 2003 Other
All Journal Article (9 results) Publications (4 results)
Gene Ther. 11
Pages: 628-635
臨床とウイルス 32
Pages: 362-371
Vaccine 20
Pages: 3149-3156
Int.J.Exp.Path. 84
Pages: 101-106
Gene Ther. 10
Pages: 2119-2125
アレルギー・免疫 10
Pages: 81-88
Vaccine 21
